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Available online 8 October 2016Objectives: In recent years several [18F]-labelled amyloid PET tracers have beendeveloped andhaveobtained clin-
ical approval. There is accumulating evidence that early (post injection) acquisitionswith these tracers are equal-
ly informative as conventional blood flow andmetabolism studies for diagnosis of Alzheimer's disease, but there
have been few side-by-side studies. Therefore, we investigated the performance of early acquisitions of [18F]-
florbetaben (FBB) PET compared to [18F]-fluorodeoxyglucose (FDG) PET in a clinical setting.
Methods: All subjects were recruited with clinical suspicion of dementia due to neurodegenerative disease. FDG
PET was undertaken by conventional methods, and amyloid PET was performed with FBB, with early recordings
for the initial 10 min (early-phase FBB), and late recordings at 90–110 min p.i. (late-phase FBB). Regional SUVR
with cerebellar and global mean normalization were calculated for early-phase FBB and FDG PET. Pearson corre-
lation coefficients between FDG and early-phase FBB were calculated for predefined cortical brain regions. Fur-
thermore, a visual interpretation of disease pattern using 3-dimensional stereotactic surface projections (3D-
SSP) was performed, with assessment of intra-reader agreement.
Results: Among a total of 33 patients (mean age 67.5 ± 11.0 years) included in the study, 18 were visually rated
amyloid-positive, and 15 amyloid-negative based on late-phase FBB scans. Correlation coefficients for early-
phase FBB vs. FDG scans displayed excellent agreement in all target brain regions for global mean normalization.
Cerebellar normalization gave strong, but significantly lower correlations. 3D representations of early-phase FBB
visually resembled the corresponding FDG PET images, irrespective of the amyloid-status of the late FBB scans.
Conclusions: Early-phase FBB acquisitions correlate on a relative quantitative and visual level with FDG PET scans,
irrespective of the amyloid plaque density assessed in late FBB imaging. Thus, early-phase FBB uptake depicts a
metabolism-like image, suggesting it as a valid surrogatemarker for synaptic dysfunction,which could ultimately
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As the most prevalent form of neurodegenerative dementias,
Alzheimer's disease (AD) is imposing an onerous burden on health
care systems in societies with aging populations (Ziegler-Graham et
al., 2008). Intracellular neurofibrillary tangles and extracellular amyloid
plaques together comprise the hallmark neuropathology of AD (Braak
and Braak, 1991). Elevated brain amyloid burden is associatedwith cog-
nitive decline in cognitively normal (CN) subjects (Lim et al., 2012), and
in cases of mild cognitive impairment (MCI), who are at high risk forer the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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loid PET radiotracers such as [18F]florbetaben (FBB) have been devel-
oped, and have proven to be sensitive indicators for brain amyloid
pathology in vivo (Barthel and Sabri, 2011). Amyloid plaques play a
role in early pathogenesis of AD, and may even be present 10–
15 years prior to onset of discernible cognitive decline, before develop-
ing to a stable level observed at the clinical stages of AD (Kadir et al.,
2012). Thus, the extensive amyloid accumulation during the pre-clinical
course may disfavor the use of FBB and related PET tracers to determine
the extent of neurodegeneration or to monitor disease progression in
clinical stages of AD (Furst et al., 2012). In contrast, findings with
more conventional [18F]fluorodeoxyglucose (FDG) PET for measuring
cerebral glucose metabolism, or perfusion SPECT scans, are a much
more sensitive indicator for disease stage, and can provide information
about synaptic dysfunction and the degree of neurodegeneration
(Herholz, 2011; Shokouhi et al., 2013).
In addition to these considerations, positive amyloid burden is seen
not only in AD but also in other neurodegenerative dementias, notably
in a subset of patients with dementia with Lewy bodies or Parkinson's
disease dementia (Donaghy et al., 2015). Accordingly, additional FDG
PET or perfusion SPECT is considered beneficial for differentiating amy-
loid pathology in AD cases from that arising in other amyloid-positive
diseases, on the basis of a disease-specific pattern of tracer impaired ce-
rebral blood flow (CBF) or energy metabolism. Even more importantly
in amyloid-negative cases, further differential diagnoses can be in-
formed by depiction of the hypometabolic/hypoperfusion pattern.
As such, combining amyloid PET with FDG PET or perfusion SPECT
delivers complementary information, which helps to improve accuracy
of AD diagnosis, and the specification of disease progression
(Ossenkoppele et al., 2013). In this regard, it seems relevant that several
recent studies have shown comparable reductions of early-phase amy-
loid PET tracer uptake andmetabolic deficits in PET using FDG (Meyer et
al., 2011; Rostomian et al., 2011; Hsiao et al., 2012; Tiepolt et al., 2016).
This concordance arises from the nature of lipophilic radiotracers such
as FBB for amyloid PET and [99mTc]-HMPAO for perfusion SPECT. In gen-
eral, these lipophilic tracers have a high first-pass influx rate (K1)
(Dishino et al., 1983), which correlates with the regional CBF due to
the high extraction fraction (K1/CBF for [11C]PiB: 77%, (Blomquist et
al., 2008)), and (due to the phenomenon of flow-metabolism coupling),
also with the metabolic rate for glucose metabolism (Silverman, 2004;
Nihashi et al., 2007; Herholz, 2011). Thus, early-phase PET images
with lipophilic tracers can serve as a surrogate for metabolism.
The aim of the present study was to investigate the comparability of
early-phase FBB PET, as a depiction of a perfusion-like image, to regional
glucose metabolism in FDG PET images, both of which are impaired in
patients with dementia. Therefore, we performed relative quantitative
cross-analyses as well as visual cross-assessments of early-phase FBB
and conventional FDG PET acquisitions, which were acquired in a clini-
cal setting of patients with suspicion of a neurodegenerative dementia
disorder.2. Methods
2.1. Study design and patient enrollment
All subjects were recruited by the Klinikum der Universität
München, the study protocol was approved by the local institution-
al review board and complied with the declaration of Helsinki. All
patients gave their written informed consent and were scanned
in a clinical setting at the Department of Nuclear Medicine. The pri-
mary objective of the prospective study is the clinical utility of FBB-
PET (N = 93 subjects), and in a subset of 33 patients early-phase
FBB acquisitions could be performed. All of these included subjects
had an additional FDG PET investigation, with b12 months be-
tween FBB and FDG PET.2.2. Radiosynthesis
Radiosynthesis of FBB was performed as described previously (Patt
et al., 2010), employing an automated synthesis module (Eckert &
Ziegler, Berlin, Germany). Radiochemical purity was N99% and specific
activity was 7.3 × 105 ± 3.4 × 105 GBqmmol−1 at the end of synthesis.
2.3. PET imaging
2.3.1. FBB PET acquisition
FBB PET images were acquired in 3D mode on a GE Discovery 690
PET/CT scanner. For those with early recordings, a dynamic emission re-
cording lasting 10 min (10 × 60 s frames) was initiated immediately
upon intravenous injection of 300 ± 5 MBq FBB, whereas late static re-
cordingswere recorded from 90min to 110min p.i. (4 × 300 s) (Barthel
et al., 2011). A low-dose CT scan was performed just prior to the static
acquisition for attenuation correction of both PET emission recordings.
PET data were reconstructed iteratively into a pair of summed early-
phase FBB images (0–5 min p.i. (FBB0–5) and 0–10 min p.i. (FBB0–10))
and one late-phase FBB image (90–110 min p.i. (FBB90–110)).
2.3.2. FDG PET acquisition
FDG PET images were acquired using a 3-dimensional GE Discovery
690 PET/CT scanner or a Siemens ECAT EXACT HR+ PET scanner. All pa-
tients fasted for at least 6 h prior to scanning, and had amaximumplasma
glucose level of 120 mg/dl at time of [18F]-FDG administration. A dose of
140 ± 7MBq [18F]-FDG was injected intravenously in resting conditions,
in a roomwith dimmed light and low noise level. A static emission frame
was acquired from 30min to 45min p.i. for the GE Discovery 690 PET/CT,
or from30 to60minp.i. for the Siemens ECATEXACTHR+PET scanner. A
low-dose CT scan or a transmission scan with external 68Ge-sources was
performedprior to the static acquisition andwasused for attenuation cor-
rection. PET data were reconstructed iteratively (GE Discovery 690 PET/
CT, voxel size 2.34 × 2.34 × 3.27 mm, 3D recon with a 4.5 mm Gaussian
post filter) or with filtered backprojection (Siemens ECAT EXACT HR+
PET, voxel-size 2.03 × 2.03 × 2.42 mm with a 2.42 mm Hann filter).
This resulted in datasets with comparable resolution (Joshi et al., 2009).
2.4. Image processing
2.4.1. Template generation
For spatial normalization, early-phase FBB (FBB0–5, FBB0–10) uptake
templates and a FDG template were created using the PMOD software
(version 3.5, PMOD Technologies Ltd., Zurich, Switzerland). First, indi-
vidual PET images (FBB0–5, FBB0–10 and FDG) from16 randomly selected
subjects were rigidly matched to the corresponding individual MR
image (T1-weighted). The individualMR images were spatially normal-
ized to a Montreal Neurological Institute (MNI) T1wMRI template, and
the individual MR-MR transformation parameters were saved. Consec-
utively the coregistered PET images were spatially normalized to the
MNI template using the individual transformation parameters, scaled
to global mean, and smoothed with an 8 mm Gaussian filter. Finally
PET templateswere generated by calculating themeanof all normalized
PET counts in FBB0–5, FBB0–10 and FDG PET, as previously described
(Meyer et al., 1999; Hsiao et al., 2013).
2.4.2. Data processing
All pairs of early-phase FBB images and all FDG imageswere spatially
normalized to the different PET MNI space templates. A total of 83 grey
matter volumes of interest (VOIs) predefined in the Hammers atlas
(Hammers et al., 2003) were applied to the spatially normalized early-
phase amyloid and FDG PET images. Data from the 83 grey matter
VOIs were combined resulting in the following cortical target brain re-
gions: frontal, sensorimotor, occipital, temporo-lateral, parietal, posteri-
or cingulate/precuneal cortex, as well as whole brain, separately for the
right and left hemispheres. As reference regions for activity
Table 1
Demographics of the study population.
Study Groups N Age (y ± SD) Gender (%-m/%-f) Mean difference between FDG and FBB PET (in month)
All subjects 33 67.5 ± 11.0 58/42 2.7 ± 3.4
Amyloid-positive 18 69.1 ± 8.7 50/50 3.0 ± 4.5
Amyloid-negative 15 66.3 ± 12.8 67/33 2.4 ± 3.4
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global mean; GLM) including CBL. For relative quantitative analysis, re-
gional standardized uptake value ratios (SUVR)were calculated for each
cortical brain VOI, with scaling for either CBL or GLM.
2.5. Image analysis
2.5.1. Late-phase FBB PET
Late-phase FBB images were visually assessed by three independent
experts in Nuclear Medicine. Patients with significantly increased corti-
cal FBB uptake in at least one cortical region were judged as amyloid-
positive according to common diagnostic criteria. A conflicting result
between readers in one case was resolved by a majority decision.
2.5.2. Relative quantitative cross-correlation of early-phase [18F]-
florbetaben PET and FDG PET
Regional initial amyloid uptake and glucose metabolism were
assessed relative quantitatively on a VOI base by comparing the regional
SUVRs of early-phase FBB PET recordings to the corresponding regional
SUVRs from FDG PET. To identify the preferable reference region, we
compared correlation coefficients of VOI-based results between early-
phase FBB and FDG images, using CBL or GLM for normalization of up-
take. Similarly, to identify the better of the two time frames for early-
phase amyloid PET imaging, we calculated correlation coefficients for
VOI results using FBB0–5 or FBB0–10 images. In both cases, the preferred
reference region or time framewas the one giving thehigher correlation
coefficients.
2.5.3. Visual analysis of stereotactic surface projections of early-phase FBB
and FDG PET
For visual interpretation of early-phase FBB PET (FBB0–5) and FDG
PET images, three-dimensional stereotactic surface projections (3D-
SSP) (Minoshima et al., 1995) were generated using the software
Neurostat (Department of Radiology, University ofWashington, Seattle,
WA, U.S.A.). Three independent experts in Nuclear Medicine visually
assessed the 3D-SSP images using tracer uptake and Z-score maps
(with GLM reference for scaling). Voxel-wise Z-scores were calculated
in Neurostat by comparing the individual tracer uptake (FBB0–5 and
FDG) to historical FDG PET scans from a healthy age-matched cohort
(N = 18). For visual analysis, the GLM normalization for FBB PET was
chosen because it imparted the visually best resemblance to the corre-
sponding FDG image which was additionally supported by relative
quantitative results. All readers were blinded to any identifying and
clinical information. All 3D-SSP images (FBB0–5 and FDG PET) were
uploaded in a random sequence, and readers were not informed of the
kind of scan (FBB0–5 or FDG). Regional abnormalities (hypoperfusion/
hypometabolism) in FBB0–5 and FDG images were graded as not rele-
vant = 0, low = 1, moderate = 2 and severe = 3 in the following re-
gions: frontal right and left, temporo-lateral right and left, parietal
right and left, posterior cingulate/precuneus for both hemispheres. A
PET diagnosis was provided by four-item judgement of the most likely
of the following diagnoses: 1. low/moderate hypoperfusion/
hypometabolism, that is suspicious of a beginning neurodegenerative
disease (e.g. exclusive hypoperfusion/hypometabolism in posterior cin-
gulate cortex), 2. AD, 3. frontotemporal lobar degeneration (FTLD) or 4.
non-AD/FTLD including rare neurodegenerative diseases such as
corticobasal syndrome, including hypoperfusion/hypometabolism that
is not specific for a neurodegenerative disease pattern (e.g. changesdue to (minor) strokes in terms of vascular dementia) and also includ-
ing no relevant hypoperfusion/hypometabolism.
2.6. Statistical analysis
Group correlations of regional SUVRs between early-phase FBB and
FDG images were evaluated using Pearson's correlation test. For visual
analysis, the intra-reader correlations between hypoperfusion in early-
phase FBB and hypometabolism in FDG images were calculated by
Spearman's rank correlation coefficient (Rs). For specification of the
most likely PET diagnosis, intra-reader agreement between early-
phase FBB and FDG was calculated using Cohen's Kappa. A significance
level of p b 0.05was applied in all analyses. All statistical testswere per-
formed using SPSS 22.0.
3. Results
3.1. Demographics
A total of 33 subjects (19 male) were included in the study. The
group consisted of 11 subjects with a clinical diagnosis ofmild cognitive
impairment (MCI) and 22 demented subjectswith different clinical pre-
sentations: 11 of these cases had amost likely diagnosis of AD, fourwere
likely suffering from FTLD, single cases of primary progressive aphasia
or corticobasal degeneration and five cases with ambiguous clinical
and biomarker presentation. The mean age was 68 ± 11 years. 18 of
33 late FBB PETs were visually classified as amyloid-positive (9 male;
mean age 69 ± 9 years), 15 of 33 as amyloid-negative (10 male; mean
age 66 ± 13 years). The mean ± SD time period between FBB and
FDG was 2.7 ± 3.4 months (Table 1).
3.2. VOI-based comparison of early-phase FBB and FDG PET
Correlation plots for FBB0–5 versus FDG PETwith GLMnormalization
are shown in Fig. 1. Regional SUVRs and correlation coefficients deter-
mined by comparing regional FBB0–5 and FBB0–10 with FDG SUVRs
(CBL and GLMnormalization) are shown in Table 2. All cortical brain re-
gions showed highly significant correlations irrespective of the early-
phase FBB time frame or the particular reference region (p b 0.0001).
The least correlationwas found in the left frontal and right sensorimotor
region (R0–5/CBL = 0.59) and the highest in the left and right parietal re-
gion, the left temporo-lateral region (R0–5/GLM = 0.92) as well as the
right parietal region (R0–10/GLM = 0.92). Overall, the highest correlation
valueswere found for a GLMnormalization irrespective of the particular
FBB time frame, for which the mean correlations among regions were
R0–5/GLM = 0.86 ± 0.05 and R0–10/GLM = 0.86 ± 0.05. In comparison,
the CBL normalization gave strong, but significantly lower correlations
(p b 0.001; paired t-test) between FBB and FDG SUVRs (R0–5/CBL =
0.75 ± 0.10 and R0–10/CBL = 0.76 ± 0.10) (Table 2).
To determine the preferable time frame for initial FBB uptake, we
compared the correlation values between FBB0–5 and FBB0–10 uptake
and FDG results. Using the GLM reference, there was no significant dif-
ference in the correlation coefficients (mean R0–5/GLM = 0.86 vs. R0–10/
GLM = 0.86; p = ns; paired t-test). In contrast, CBL normalization gave
slightly stronger correlations for a time frame of 0–10 min (mean R0–
5/CBL = 0.75 vs. mean R0–10/CBL = 0.76; p b 0.05; paired t-test).
All relative quantitative analyses were repeated after splitting the
cohort into an amyloid-positive (n = 18) and amyloid-negative (n =
Fig. 1. Correlation charts of early-phase FBB0–5 and FDG SUVRs (global mean normalization). R: right; L: left; PCC: posterior cingulate cortex; **p b 0.01.
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Table 2
Regional SUVRs and correlation coefficients of early-phase FBB and FDG with cerebellar and global mean normalization.
R: right; L: left; PCC: posterior cingulate cortex; **p b 0.01.
All subjects Global mean normalization Cerebellum normalization
Region Early-phase [18F]-florbetaben PET [18F]-FDG
PET














Frontal R 1.19 ± 0.06 0.82** 1.18 ± 0.05 0.81** 1.19 ± 0.07 0.99 ± 0.07 0.65** 1.00 ± 0.06 0.69** 1.09 ± 0.09
Frontal L 1.14 ± 0.06 0.85** 1.13 ± 0.06 0.83** 1.14 ± 0.06 0.95 ± 0.06 0.59** 0.96 ± 0.05 0.60** 1.05 ± 0.08
Sensorimotor R 1.18 ± 0.05 0.80** 1.17 ± 0.05 0.79** 1.20 ± 0.07 0.98 ± 0.07 0.59** 0.99 ± 0.06 0.60** 1.10 ± 0.08
Sensorimotor L 1.16 ± 0.07 0.77** 1.14 ± 0.07 0.77** 1.16 ± 0.08 0.96 ± 0.08 0.66** 0.97 ± 0.07 0.65** 1.07 ± 0.10
Occipital R 1.30 ± 0.06 0.81** 1.28 ± 0.06 0.82** 1.26 ± 0.07 1.08 ± 0.09 0.70** 1.09 ± 0.07 0.73** 1.16 ± 0.08
Occipital L 1.30 ± 0.08 0.90** 1.28 ± 0.08 0.90** 1.27 ± 0.10 1.08 ± 0.09 0.78** 1.09 ± 0.07 0.78** 1.16 ± 0.10
Parietal R 1.15 ± 0.08 0.92** 1.14 ± 0.08 0.92** 1.16 ± 0.09 0.96 ± 0.10 0.83** 0.98 ± 0.09 0.85** 1.07 ± 0.12
Parietal L 1.12 ± 0.08 0.92** 1.12 ± 0.07 0.90** 1.13 ± 0.10 0.94 ± 0.09 0.82** 0.96 ± 0.08 0.82** 1.04 ± 0.12
PCC R 0.92 ± 0.10 0.89** 0.95 ± 0.08 0.91** 0.98 ± 0.09 0.76 ± 0.10 0.86** 0.81 ± 0.09 0.88** 0.90 ± 0.11
PCC L 1.04 ± 0.08 0.82** 1.05 ± 0.06 0.88** 1.08 ± 0.09 0.86 ± 0.08 0.76** 0.90 ± 0.07 0.78** 0.99 ± 0.11
Temporo-lateral
R
1.07 ± 0.06 0.88** 1.08 ± 0.06 0.87** 1.07 ± 0.06 0.89 ± 0.08 0.85** 0.92 ± 0.07 0.88** 0.98 ± 0.07
Temporo-lateral L 1.04 ± 0.06 0.92** 1.05 ± 0.05 0.91** 1.03 ± 0.08 0.87 ± 0.08 0.85** 0.89 ± 0.06 0.86** 0.95 ± 0.09
Whole R 1.14 ± 0.04 0.86** 1.14 ± 0.04 0.87** 1.14 ± 0.04 0.95 ± 0.07 0.70** 0.97 ± 0.06 0.74** 1.05 ± 0.07
Whole L 1.12 ± 0.04 0.87** 1.12 ± 0.03 0.83** 1.12 ± 0.05 0.93 ± 0.06 0.70** 0.95 ± 0.05 0.65** 1.03 ± 0.07
81S. Daerr et al. / NeuroImage: Clinical 14 (2017) 77–8615) subgroup. The corresponding SUVRs and correlation coefficients are
shown in Table 3A and B. All brain regions in the amyloid-positive co-
hort aswell as nearly all in the amyloid-negative cohort (with exception
of right sensorimotor cortexwith CBL normalization and FBB0–10 (R0–10/Table 3
Regional SUVRs and correlation coefficients of early-phase FBB and FDG of amyloid-positive (A
R: right; L: left; PCC: posterior cingulate cortex; **p b 0.01.
Region Global mean normalization









Frontal R 1.20 ± 0.07 0.82** 1.19 ± 0.05 0.82** 1.21 ±
Frontal L 1.14 ± 0.07 0.92** 1.14 ± 0.06 0.91** 1.15 ±
Sensorimotor R 1.19 ± 0.06 0.84** 1.18 ± 0.05 0.85** 1.21 ±
Sensorimotor L 1.16 ± 0.06 0.78** 1.15 ± 0.05 0.77** 1.16 ±
Occipital R 1.29 ± 0.07 0.90** 1.27 ± 0.06 0.90** 1.27 ±
Occipital L 1.29 ± 0.09 0.93** 1.27 ± 0.08 0.93** 1.26 ±
Parietal R 1.15 ± 0.08 0.96** 1.15 ± 0.08 0.95** 1.16 ±
Parietal L 1.12 ± 0.09 0.97** 1.12 ± 0.08 0.95** 1.12 ±
PCC R 0.91 ± 0.10 0.92** 0.95 ± 0.07 0.93** 0.98 ±
PCC L 1.04 ± 0.08 0.84** 1.06 ± 0.06 0.90** 1.09 ±
Temporo-lateral
R
1.06 ± 0.08 0.92** 1.07 ± 0.07 0.91** 1.07 ±
Temporo-lateral L 1.01 ± 0.07 0.94** 1.03 ± 0.06 0.93** 1.00 ±
Whole R 1.14 ± 0.04 0.93** 1.14 ± 0.04 0.95** 1.15 ±
Whole L 1.11 ± 0.04 0.91** 1.11 ± 0.04 0.89** 1.11 ±
Amyloid-negative
Frontal R 1.17 ± 0.04 0.74** 1.16 ± 0.04 0.67** 1.15 ±
Frontal L 1.13 ± 0.05 0.68** 1.13 ± 0.05 0.63** 1.14 ±
Sensorimotor R 1.17 ± 0.05 0.71** 1.16 ± 0.04 0.69** 1.18 ±
Sensorimotor L 1.15 ± 0.09 0.84** 1.14 ± 0.08 0.85** 1.17 ±
Occipital R 1.31 ± 0.05 0.72** 1.29 ± 0.05 0.74** 1.26 ±
Occipital L 1.31 ± 0.07 0.83** 1.29 ± 0.06 0.83** 1.27 ±
Parietal R 1.15 ± 0.09 0.88** 1.14 ± 0.08 0.89** 1.16 ±
Parietal L 1.13 ± 0.08 0.85** 1.13 ± 0.07 0.84** 1.15 ±
PCC R 0.92 ± 0.11 0.89** 0.95 ± 0.10 0.90** 0.97 ±
PCC L 1.04 ± 0.09 0.80** 1.05 ± 0.08 0.86** 1.07 ±
Temporo-lateral
R
1.07 ± 0.05 0.78** 1.08 ± 0.05 0.77** 1.07 ±
Temporo-lateral L 1.07 ± 0.04 0.79** 1.07 ± 0.03 0.78** 1.07 ±
Whole R 1.14 ± 0.03 0.75** 1.13 ± 0.31 0.73** 1.13 ±
Whole L 1.13 ± 0.03 0.78** 1.12 ± 0.31 0.73** 1.13 ±CBL = 0.41)) showed significant regional correlation values between
early-phase FBB results and FDG images (with either CBL or GLM nor-
malization). Significantly higher correlations were observed in the am-
yloid-positive group (e.g. mean R0–5/GLM = 0.90 (for amyloid-positive)) and amyloid-negative (B) subjects.
Cerebellum normalization








0.08 0.99 ± 0.07 0.64** 1.01 ± 0.06 0.73** 1.11 ± 0.09
0.07 0.94 ± 0.06 0.64** 0.97 ± 0.05 0.71** 1.05 ± 0.09
0.07 0.98 ± 0.08 0.70** 1.00 ± 0.06 0.75** 1.11 ± 0.08
0.09 0.96 ± 0.08 0.68** 0.98 ± 0.06 0.71** 1.06 ± 0.10
0.07 1.07 ± 0.08 0.70** 1.08 ± 0.07 0.79** 1.16 ± 0.08
0.11 1.07 ± 0.10 0.80** 1.08 ± 0.07 0.85** 1.15 ± 0.10
0.09 0.95 ± 0.10 0.87** 0.98 ± 0.09 0.92** 1.06 ± 0.11
0.11 0.92 ± 0.09 0.87** 0.95 ± 0.07 0.92** 1.02 ± 0.13
0.08 0.75 ± 0.08 0.85** 0.81 ± 0.07 0.83** 0.90 ± 0.09
0.09 0.86 ± 0.06 0.78** 0.90 ± 0.05 0.75** 0.99 ± 0.09
0.07 0.88 ± 0.09 0.84** 0.91 ± 0.08 0.92** 0.98 ± 0.08
0.08 0.84 ± 0.08 0.84** 0.87 ± 0.06 0.89** 0.92 ± 0.10
0.04 0.95 ± 0.07 0.72** 0.97 ± 0.06 0.83** 1.05 ± 0.07
0.05 0.92 ± 0.06 0.67** 0.94 ± 0.04 0.75** 1.01 ± 0.07
0.04 0.98 ± 0.07 0.68** 0.99 ± 0.07 0.61** 1.07 ± 0.08
0.05 0.95 ± 0.06 0.52* 0.96 ± 0.06 0.46* 1.05 ± 0.08
0.07 0.98 ± 0.06 0.45* 0.99 ± 0.06 0.41 1.09 ± 0.09
0.07 0.97 ± 0.08 0.65** 0.97 ± 0.08 0.63** 1.08 ± 0.09
0.07 1.01 ± 0.07 0.72** 1.10 ± 0.07 0.67** 1.16 ± 0.09
0.09 1.10 ± 0.07 0.75** 1.10 ± 0.06 0.68** 1.18 ± 0.10
0.09 0.97 ± 0.11 0.80** 0.97 ± 0.08 0.79** 1.07 ± 0.13
0.09 0.96 ± 0.10 0.74** 0.96 ± 0.09 0.72** 1.07 ± 0.12
0.10 0.78 ± 0.12 0.88** 0.81 ± 0.11 0.90** 0.90 ± 0.13
0.10 0.87 ± 0.10 0.76** 0.89 ± 0.09 0.79** 0.99 ± 0.13
0.05 0.90 ± 0.08 0.87** 0.92 ± 0.08 0.85** 0.99 ± 0.06
0.05 0.90 ± 0.06 0.84** 0.91 ± 0.06 0.79** 0.99 ± 0.07
0.03 0.96 ± 0.07 0.71** 0.97 ± 0.06 0.66** 1.05 ± 0.08
0.04 0.95 ± 0.06 0.63** 0.96 ± 0.05 0.58* 1.04 ± 0.07
Table 4
Mean correlation coefficients of early-phase FBB vs. FDG.
GLM: global mean normalization, CBL: cerebellum normalization; *p b 0.05; **p b 0.01.
Parameters (reference region, time frame) Mean R between early-phase FBB and FDG
All Amyloid-positive Amyloid-negative
GLM, 0–5 min 0.86 ± 0.05 0.90 ± 0.06 0.79 ± 0.07
GLM, 0–10 min 0.86 ± 0.05 0.90 ± 0.06 0.79 ± 0.09
CBL, 0–5 min 0.75 ± 0.10 0.77 ± 0.09 0.72 ± 0.13
CBL, 0–10 min 0.76 ± 0.10 0.81 ± 0.08 0.69 ± 0.15
82 S. Daerr et al. / NeuroImage: Clinical 14 (2017) 77–86versusmean R0–5/GLM= 0.79 (for amyloid-negative), p b 0.001). For the
entire cohort, the regional SUVRs with a GLM normalization showed
better correlations between early-phase FBB and FDG than did SUVRs
with CBL normalization; there was no difference between correlations
for FBB0–5 and FBB0–10 results when using the GLM normalization,
whereas CBL normalization gave better correlations for FBB0–10 in the
amyloid-positive subgroup and for FBB0–5 in the amyloid-negative sub-
group (Table 4).Fig. 2. 3D-SSP images of a 79 year oldmale personwith clinical presentation of AD (A) and an 81
for FDG (upper row) and FBB0–5. The map depicts areas with less uptake compared to normal3.3. Visual 3D-SSP comparison of early-phase FBB and FDG
After identifying the optimal time frame and reference region, visual
assessment was performed by evaluating 3D-SSP images of early-phase
FBB0–5 and FDG images of tracer uptake and Z-scores (with GLM nor-
malization). Fig. 2A shows 3D-SSP images for a 79 year old male with
clinical presentation of AD, Fig. 2B an 81 year oldmale with clinical pre-
sentation of FTLD. The regional pattern of the perfusion surrogate inyear oldmale personwith clinical presentation of FTLD (B). Normalized count and Z-maps
controls. R: right; L: left; PCC: posterior cingulate cortex
Fig. 3. Correlation of visual scores for hypoperfusion/hypometabolism severity by three readers in early-phase FBB0–5 and FDG images.
83S. Daerr et al. / NeuroImage: Clinical 14 (2017) 77–86early-phase FBB0–5 images resembles the FDG uptake pattern, as can be
seen both in an amyloid-positive and amyloid-negative case.
The visual assessment of all target regions in all 33patients showed a
Spearman's rank correlation coefficient between FBB0–5 and FDG of=0.87 =0.79
Fig. 4. Agreement and mismatch of individual PET diagnosis in visual interpretation of early-ph
degeneration.Rs = 0.70 for reader 1, Rs = 0.77 for reader 2 and Rs = 0.75 for reader
3 (mean Rs = 0.74) (Fig. 3). Regarding Fig. 3 reader 1 and 3 have a con-
siderable number of assessed regions with early FBB = 1 and FDG= 0.
This could lead to the interpretation that early FBB images may=0.79
ase FBB0–5 and FDG 3D–SSP images. AD: Alzheimer's disease; FTLD: Frontotemporal lobar
84 S. Daerr et al. / NeuroImage: Clinical 14 (2017) 77–86demonstratemore severe hypoperfusion. In relative quantitative analy-
sis this does not prove true (SUVR(FBB0–5) vs. SUVR (FDG), p = ns).
Specifying the most likely diagnosis using 3D-SSP images of early-
phase FBB and FDG PET, reader 1 showed an overlapping diagnosis in
30 of 33 patients corresponding to an intra-reader agreement of κ =
0.87. Readers 2 and 3 showed an overlap in 28 of 33 patients, corre-
sponding to intra-reader agreements of κ = 0.79 (mean κ = 0.82,
p b 0.0001). Therewere a total of 13 cases (in 9 patients; 5 amyloid-neg-
ative, 4 amyloid-positive) of a mismatched PET diagnosis in 99 compar-
isons performed by the three readers. In four of these 13 cases, the
discrepant classification was non-AD/FTLD versus beginning neurode-
generative disease, another four cases beginning neurodegenerative
disease versus AD or FTLD, in three cases there were diagnoses of non-
AD/FTLD versus AD or FTLD, and in two cases AD versus FTLD (Fig. 4).
4. Discussion
Whereas previous studies of this type have had their main focus on
VOI-based or voxel-based statistical analysis of early-phase amyloid
PET (Meyer et al., 2011; Hsiao et al., 2012), it was our aim to investigate
the clinical use of FBB PET by additional visual interpretation of early-
phase FBB acquisitions. Our results demonstrate the strong visual and
relative quantitative correlations of initial FBB uptake with FDG images,
irrespective of the amyloid status demonstrated by the late-phase FBB
scans. Thus, early-phase FBB acquisitions, which are highly weighted
to cerebral perfusion, seem to be a valid surrogate marker for synaptic
andmetabolic dysfunction. A brief additional FBB recording in the initial
minutes after tracer injection afford supplemental information about
neuronal activity, which we believe can ultimately obviate the need
for an FDG PET scan. For patients, this means less exposure to radiation
and sparing of an additional visit to the clinic. Not to be disregarded, the
greater comfort of persons investigated for a neurodegenerative disease
might well lead to improved patient and caregiver compliance.
The results of relative quantitative, VOI-based statistical analysis
show a strong correlation of regional tracer uptake (SUVR) in all inves-
tigated cortical brain regions between initial FBB uptake and FDG PET.
This is in perfect agreement with previous studies detecting high corre-
lations between amyloid ([11C]-PIB and [18F]-AV45) R1 images derived
from the simplified reference tissue analysis (where R1 is an index of
relative CBF), as well as early time frame images of [11C]PiB or FBB and
FDG PET (Meyer et al., 2011; Rostomian et al., 2011; Hsiao et al., 2012;
Tiepolt et al., 2016). The study of Tiepolt et al. investigating a mixed co-
hort of early [11C]-PIB and early FBB scans found regional correlation
values ranging from r = 0.609 to r = 0.788 (using a time frame of 1–
9 min and CBL as the reference region). Using comparable parameters
with a time frame of 0–10 min and CBL as the reference region we
found correlation values ranging from r= 0.60 to r = 0.88. The slightly
lower correlations in the work of Tiepolt et al. may be explained by the
smaller sample size and the different tracers, since they showed stron-
ger correlations between early FBB and FDG compared to early [11C]-
PIB and FDG.
After splitting the whole cohort into amyloid-positive and amyloid-
negative subgroups, there emerged even higher correlation values in
those with amyloidosis, irrespective of the reference region or the
time frame (0–5 or 0–10min). This may be explained by a greater prev-
alence of neurodegenerative cases (especially AD) in conjunction with
rather more severe hypoperfusion/hypometabolism in the amyloid-
positive group, i.e. greater dynamic range, which leads to better separa-
tion. On the other hand, the amyloid-negative subgroup consisted of
fewer cases with severe hypoperfusion/hypometabolism, manifesting
in less defects in the early-phase FBB images. Besides, the higher corre-
lation values in the amyloid-positive subgroup may as well be influ-
enced by the larger cohort compared to the amyloid-negative
subgroup (n= 18 vs. n = 15). That the amyloid-positive cases showed
excellent correlations between early-phase FBB PET and metabolism in
FDG PET lends further support to the contention that present corticalamyloid pathology need not have a relevant effect on the extent of per-
fusion/metabolism coupling (Spehl et al., 2015), although this may still
require additional validation. We found best correlations between the
two PET measures for GLM normalization, and slightly lower correla-
tions for CBL normalization. CBL VOIs are typically used as the preferred
reference region for calculation of SUVRs because of low or absent am-
yloid plaque burden in the cerebellar cortex of AD patients (Svedberg
et al., 2009; Barthel et al., 2011). Especially for longitudinal evaluations
of late amyloid PET, it is self-evident that the reference region should
not itself be affected by amyloid deposition. In the present context, im-
ages of initial FBB uptake do not reflect amyloid burden per se, but are
rather a surrogate of CBF, due to the very first pass high extraction of
FBB and other lipophilic tracers. We note that cerebellar perfusion can
itself be affected by crossed cerebellar diaschisis in neurodegenerative
diseases, whichmight propagate to bias in normalized SUV calculations.
While there is generally good coupling between CBF and metabolism,
others have shown that the CBL is relatively hyperperfused compared
to its rate of glucose metabolism (Gur et al., 2009). As such, the CBL
need not be considered entirely privileged with respect to perfusion
changes in neurodegenerative diseases. However, it remains unclear if
this is the cause for our present finding of lower correlation values
when using CBL rather than GLM normalization. Further studies, per-
haps using data-driven methods (Dukart et al., 2013), might identify
an even better reference region for SUVR-based analysis of early-
phase amyloid PET.
To define the FBB time framewith highest correlation tometabolism
we compared early-phase (FBB0–5 and FBB0–10) FBB acquisitions to FDG
PET. Given theGLMnormalized SUVRs,we observed nodifference in the
correlations resulting from the two early frame dimensions. In contrast,
when using the CBL as the normalization reference region, there were
some inconsistent results.Whereas the time frame of 0–10min seemed
to provide better results in the amyloid-positive subgroup, the time
frame of 0–5 min was superior in the amyloid-negative subgroup,
which is likely to have less severe perfusion and metabolism defects.
Previous studies have compared a range of early-phase amyloid PET
time frames with respect to correlations with FDG PET using voxel-
wise or regional analyses. One study indicated a superior time window
of 1–8 min p.i. for [11C]-PIB (Rostomian et al., 2011), whereas another
study found best agreement with 1–6 min p.i. for the case of [11C]AV-
45 (Hsiao et al., 2012). There may be no universally applicable time
frame for such purposes, since the time interval for optimal perfusion
weighting will depend on the particular amyloid tracer, administration
technique, and perhaps also the extent of degenerative changes (as sug-
gested by our somewhat different results for amyloid-positive and
-negative subgroups). Taken together, we found no significant differ-
ence between 5 and 10 min acquisitions and therefore suggest for the
latest generation of PET scanners, for the sake of patient comfort and
economy, the shorter acquisition protocol. In case of older and less sen-
sitive PET scanners a longer acquisition timemight be useful in order to
ensure sufficient count statistics.
In the second part of our study we visually analyzed the compara-
bility of initial FBB uptake to FDG 3D-SSP images using tracer count
rates and Z-score maps, for which we employedmaps with GLM nor-
malization. The decision was based on the visually-judged greater
resemblance of the resultant images to the corresponding FDG im-
ages. In contrast, CBL, thalamus and pons normalizations simulated
severe hypoperfusion of cortical areas in the 3D-SSP images of initial
FBB uptake. This might arise from a relative hyperperfusion com-
pared to metabolism in subcortical regions, as seen in a previous
study (Gur et al., 2009), and as supported by the high perfusion-to-
metabolism ratio reported for CBL and thalamus (Hsiao et al.,
2012). To investigate the similarity of early-phase amyloid PET and
FDG PET regarding the occurrence of hypometabolism/hypoperfu-
sion, we had three independent readers grading the severity of
hypometabolism/hypoperfusion (levels 0–3) in four target regions
in both hemispheres. Using the Spearman's rank correlation test, all
85S. Daerr et al. / NeuroImage: Clinical 14 (2017) 77–86three readers returned highly significant correlations, representing a
very good intra-reader agreement. These findings underline the
highly significant results that can be derived from relative quantita-
tive analyses, and demonstrate that comparability between these
methods is not only limited to relative quantitative PET, but also
for visual analyses of initial FBB uptake and FDG images. Consistently
to our findings the study of Tiepolt et al. showed concordant regional
hypoperfusion/hypometabolism scores (levels 0–4) in 94.7% of 132
visually scored brain VOIs in 11 early FBB and the corresponding
FDG scans (95.5% in 11 early [11C]-PIB and FDG scans) (Tiepolt et
al., 2016).
For the clinical routine it is not only important that there is compa-
rable intensity of early-phase FBB and FDG uptake, it is also important
to make the correct diagnosis on the basis of the individual tracer up-
take patterns. Therefore three readers specified the most likely PET di-
agnosis from among four entities, likely to be encountered in this
setting: beginning neurodegenerative disease, AD, FTLD or non-AD/
FTLD. Reader 1 performed with almost perfect (κ = 0.87) intra-reader
agreement, whereas readers 2 and 3 still had substantial overlap (κ =
0.79) in a blinded reading without any clinical information. It needs to
be emphasized that this was an unselected cohort of MCI and otherwise
demented patients, with some ambiguous cases with diverse tracer up-
take patterns ranging fromminimal hypometabolism/hypoperfusion to
the uptake pattern characteristic of rare neurodegenerative diseases
(e.g. progressive supranuclear palsy). A priori knowledge of the clinical
presentation or additional neuro-imaging (MRI/CT) results as it is stan-
dard in clinical routine PET imaging, could well facilitate finding the
most likely diagnosis, and might have resulted in an even better intra-
reader agreement. In summary, the results of visual assessment in the
present study demonstrate the comparability of early-phase FBB and
FDG 3D-SSP images.
As a limitation of this study the absence of an early-phase FBB
healthy control database needs to be mentioned. Thus voxel-wise Z-
scores of early-phase FBB uptake were calculated by comparing the
FBB tracer uptake to FDG PET data from a healthy age-matched cohort.
Another limitation is due to the fact that FBB and FDG PET scans were
in part recorded on different PET scanners, however the reconstruction
methods used we were able to harmonize the scanner resolution as
much as possible, making a major impact unlikely.5. Conclusions
The present study demonstrates that the initial [18F]-florbetaben
uptake correlates both relative quantitatively and visually highly
with FDG images, irrespective of the particular amyloid status.
Thus, [18F]-florbetaben uptake in the first ten minutes post injection
yields a perfusion-like image, evidently serving as a valid surrogate
marker for synaptic and metabolic dysfunction, otherwise revealed
in a separate FDG PET scan. Thus, a two-phase [18F]-florbetaben pro-
tocol might in the future give unambiguous combined neurodegen-
eration and amyloid pathology biomarker information, while
sparing the patient radiation exposure from an additional FDG PET
scan. The optimal relative quantitative analysis of early-phase [-
18F]florbetaben acquisitions arises from GLM normalization, with lit-
tle effect of the particular time frame (0–5 or 0–10min), favoring the
shorter time in up-to-date PET scanners due to patient comfort and
economic reasons.Conflict of interest
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